Orchestra BioMed Holdings, Inc. (OBIO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 47/100 (MEDIUM), 19.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 7.07% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
- Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
- Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Orchestra BioMed Holdings, Inc..
Full OBIO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.